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ABSTRACT:  Well-established cell culture models were combined with new analytical methods to assess 
the effects of small molecules on the cholesterol biosynthesis pathway. The analytical protocol, which is 
based on sterol derivation with the dienolphile PTAD, was found to be reliable for the analysis of 7-DHC 
and desmosterol. The PTAD method was applied to the screening of a small library of pharmacologically 
active substances and the effect of compounds on the cholesterol pathway was determined. Of some 727 
compounds, over 30 compounds decreased 7-DHC in Dhcr7-deficient Neuro2a cells. The examination of 
chemical structures of active molecules in the screen grouped the compounds into distinct categories. In 
addition to statins, our screen found that SERMs, antifungals, and several anti-psychotic medications 
reduced levels of 7-DHC. The activities of selected compounds were verified in human fibroblasts derived 
from Smith-Lemli-Opitz syndrome (SLOS) patients and linked to specific transformations in the cholesterol 
biosynthesis pathway. 
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3
The biosynthesis of cholesterol is a complex process that involves multiple enzymes and intermediates.
1
 
The pathway from lanosterol to cholesterol includes over a dozen metabolic intermediates, many of which 
play important roles in cellular processes such as hedgehog signal transduction.
2-4
 Cholesterol is of critical 
importance in myelination and normal brain cholesterogenesis is absolutely essential for normal embryonic 
and perinatal development.  Genetic errors affecting transformations that are early in the biosynthesis 
pathway are generally lethal at pre-implantation or the very early embryonic stage while individuals with 
inborn errors affecting the last steps of cholesterol biosynthesis can survive to birth, usually with severe 
consequences. 
5-16
   
Figure 1 shows structures of three late-stage sterols in 
the post-lanosterol pathway.  7-Dehydrocholesterol (7-
DHC) and desmosterol are the immediate biosynthetic 
precursors of cholesterol and there are known human 
disorders associated with errors in the conversion of these 
sterols to cholesterol.
5,6
 7-DHC accumulates in patients 
with Smith-Lemli-Opitz syndrome (SLOS),
7
 a metabolic 
disorder resulting from mutations in the gene encoding 7-
dehydrocholesterol reductase (DHCR7), the enzyme that 
catalyzes the reduction of 7-DHC to cholesterol.
8,9
  
 
The pathophysiology of SLOS is the apparent result of changing the cholesterol/7-DHC balance in these 
individuals. The physiological concentration of 7-DHC in healthy human plasma is very low (0.005 to 0.05 
mg/dl) while in persons with SLOS it is greatly elevated (typically 10 mg/dl or greater) and cholesterol levels 
are typically reduced substantially.  Cholesterol supplementation is a standard clinical treatment for patients 
with SLOS but in practice this treatment shows only limited efficacy in improving the behavioral phenotype: 
  
 
Figure 1.  Late-stage Sterols in Cholesterol 
Biosynthesis 
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4
cholesterol from the systemic circulation does not penetrate the blood-brain barrier, thus limiting the 
beneficial effects on the brain. 
Statins were also a logical, pathophysiology-based therapy for patients with SLOS – alone, or in  
combination with cholesterol supplementation.
17-19
 Unfortunately, in clinical practice the benefit for the 
patients is questionable, and several studies did not confirm the previously reported positive effect of 
simvastatin treatment on anthropometric measures or behavior of patients. The biosynthetic pathway between 
HMG-CoA reductase and DHCR7 is long and complex, with various intercalated metabolic pathways, and 
inhibition of HMG-CoA reductase non-selectively represses the whole cholesterol biosynthesis machinery, 
potentially further reducing the already diminished cholesterol in SLOS patients. 
Recent evidence supports the notion that the lack of cholesterol is only partly responsible for the SLOS 
pathophysiology and pathology. 7-DHC is one of the most reactive lipids known toward free radical 
peroxidation, its rate constant for propagation being 200 times that of cholesterol and 12 times greater than 
arachidonic acid, a lipid generally thought to be highly reactive.
20
 The accumulating 7-DHC is a highly 
reactive lipid molecule, and it undergoes spontaneous free radical peroxidation, producing over a dozen 
oxidation products (i.e., oxysterols) in vitro and in vivo. These 7-DHC-derived oxysterols exert cytotoxicity, 
reduce cell proliferation, and induce premature cell differentiation and lead to a host of gene expression 
changes.
21,22
 At nanomolar concentrations in brain tissues of a Dhcr7-KO mouse, 7-DHC oxysterols are 
strongly neurotoxic.  Indeed, oxysterols found in concentrations as high as 3 µM in the KO mouse brain 
dramatically accelerate differentiation and neurite outgrowth in neocortical neuronal cultures.
22
 The 
accumulation of 7-DHC leads to a brain region-specific formation of 7-DHC-derived oxysterols that affect 
expression of many transcripts,
23,24
 leading to premature neuronal differentiation, most likely due to oxysterol 
formation in the brain tissue. 
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5
In summary, recent studies reveal that the accumulation of 7-DHC and its related oxysterols might 
significantly contribute to the pathogenesis of SLOS, which points to a new direction of therapeutic approach 
– inhibition of the formation and accumulation of 7-DHC and restoring the 7-DHC/cholesterol ratio. 
Desmosterolosis, an autosomal recessive disorder, is even rarer than SLOS.
11
 The mutation in this 
syndrome is in the gene encoding DHCR24, the enzyme that converts desmosterol to cholesterol. 
Desmosterol accumulates in these patients and the diagnostic assessment of this syndrome and of SLOS is by 
analysis of the blood sterol profile.
12-16
 Blood and skin cell sterol profile testing is also used for the diagnosis 
of the Antley-Bixler, SC4MOL, CDPX2/Conradi Hunermann and lathosterolosis disorders, each of which 
results from defective enzymes promoting a step in the biosynthetic pathway upstream from DHCR24 and 
DHCR7.
11
 
Sterol Homeostasis and Small Molecules.  Recent reports have noted that some prescribed pharmaceuticals 
have a marked effect on sterol profiles, in some cases leading to plasma levels of 7-DHC in individuals that 
are as high as those found in some SLOS patients.  One recent study examined the medical records of 
patients with elevated levels of 7-DHC in the absence of a DHCR7 mutation and found a number of 
individuals who were SLOS false positives and who also had reported a history of treatments with 
aripiprazole, an atypical antipsychotic, and trazodone, an antidepressant.
25,26
 Other small molecules have 
been found to perturb sterol profiles in cell culture and some of these compounds are also prescribed 
antipsychotic agents.
3,27-30
 AY9944, a small molecule synthesized as a potential cholesterol-lowering agent 
was found to increase 7-DHC and reduce cholesterol levels in rodents.
31-40
 
What seems clear is that exposure to small molecules, some of which are a part of the US Pharmacopeia, 
can have a profound effect on sterol profiles in vivo. Consideration of these previous studies also suggests 
that a screening method to identify compounds that affect sterol homeostasis might find general use.
41,42
 We 
report here the results of a preliminary screen of the compounds in the NIH Clinical Collection, a small 
library of pharmacologically active molecules.  The primary screening method relies on a liquid 
chromatography mass spectrometry (LC-MS) analysis of late-stage cholesterol biosynthetic intermediates 
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6
including 7-DHC, desmosterol, 7-dehydrodesmosterol (7-DHD) and lanosterol. Dhcr7-deficient Neuro2a 
cells prove to be particularly convenient for the screen in a 384-well format. The LC-MS sterol analysis in 
combination with these cells distinguishes not only small molecules that increase levels of 7-DHC but also 
those that lower levels of this potentially toxic cholesterol precursor. The activities of selected compounds 
were tested in SLOS human fibroblasts to determine the utility of the approach in identifying compounds that 
may prove beneficial and/or test the potential toxic side-effect of drugs that may be in therapeutic use in 
SLOS patients. 
Results 
We selected Neuro2a and Dhcr7-deficient Neuro2a for the high-throughput screening. Neuro2a cells, a 
mouse neuroblastoma cell line, are widely used in the neuroscience community as models of neuronal cell 
culture.
21,23,42-46
 These cells express all of the 
enzymes in the cholesterol biosynthesis 
pathway and they survive in a lipid free 
medium by endogenous biosynthesis.  To 
better understand the molecular 
consequences of DHCR7 deficiency in 
neuronal cells we generated Dhcr7-deficient 
Neuro2a cells using an shRNA approach.
42
 
Dhcr7-deficient cells have downregulated 
lipid and other transcripts (molecules that 
play critical roles in proliferation and 
differentiation, intracellular signaling, vesicular transport, or are inserted into membrane rafts), and they have 
greatly increased 7-DHC and the 7-DHC derived oxysterol DHCEO.
23,41 
Both control and Dhcr7-deficient 
cells are sensitive to compounds that affect either Dhcr7 or Dhcr24 expression levels. These cells have 
several benefits as the basis for a small-molecule screening program.  The advantages also include fast 
 
 
Figure 2. PTAD, its 7-DHC Diels-Alder Adduct (7-DHC-
PTAD) and the Desmosterol Products of PTAD in 
Methanol. 
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7
proliferation as their doubling time is about 20 hrs.  They grow well under a variety of cell culture conditions, 
including with serum-deficient and lipid-deficient media. Although we used both cell types in the screening 
procedure, Dhcr7-deficient cells were the better choice to monitor decreases of 7-DHC levels since control 
Neuro2a cells have very low levels of 7-DHC compared to Dhcr7-deficient cells.
47
 
 
Sterol Assay. The LC-MS analysis relies on a derivatization strategy 
that makes use of the reactive compound 4-phenyl-1,2,4-triazoline-
3,5-dione (PTAD, see Figure 2).47 This dienophile reacts with 7-DHC 
in a Diels-Alder cycloaddition and in the process introduces five 
heteroatoms into the adduct structure, 7-DHC-PTAD,48-50 improving 
the MS detection sensitivity for the sterol (Figure 2).51,52 The workup 
for cultured cells involves lysis in methanol, agitation with a 
PTAD/methanol solution for 20 min at RT followed by isocratic 
UPLC-MS on C18 with methanol mobile phase. A typical UPLC-MS 
run of Dhcr7-deficient Neuro2a cells in culture is shown in Figure 3.  
Under our current conditions, 50-60 samples/hr can be processed from 
a multi-well culture plate. A deuterated 7-DHC standard (d7-7-DHC) 
was synthesized permitting a quantitative assay with limits of 
detection of 7-DHC-PTAD less than 0.1 picograms, see peaks eluting 
at 0.81 min in Figure 3.  
Desmosterol, lanosterol and other sterols having a double bond at 
C24-25 undergo reaction with PTAD by the “ene” reaction as shown in Figure 2 and these “ene” type 
products are monitored in the UPLC-MS.53-57 Isotopically-labeled standards for desmosterol (0.53 minutes) 
and lanosterol (0.57 minutes) containing 
13
C carbons at C24, C25 and C26 were prepared and can be used for 
analysis of these sterols, see Figure 3. We conclude further that UPLC separations and mass differences of 
 
Figure 3. UPLC-MS chromato-
gram of PTAD Assay for Dhcr7-
deficient Neuro2a cells. Shown are 
selective reaction monitoring of 7-
DHC and its isotopic standard (d7-
7DHC), desmosterol (Des), lanosterol 
(Lan) and their 
13
C-isotopic standards 
(3
13
C-Des) and (3
13
C- Lan).  
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8
the PTAD adducts permit quantitative assays of the sterols mentioned above.  Lanosterol-PTAD/MeOH, for 
example, can be readily distinguished from other PTAD products by its mass. 
Critical to the expansion of the assay to other sterols is the availability of isotopically labeled standards to 
be added to cells, tissues or fluids before workup.  The standard must be present in the sample before the 
PTAD procedure is initiated so that standard and analyte undergo the same derivatizations.  
Screens of Presumed “Active” Compounds.  
Our first studies were carried out in control 
Neuro2a cells in 96-well plates. To determine 
the utility of the PTAD assay in cultured cells 
we measured 7-DHC in a specified number 
of both control and Dhcr7-deficient Neuro2a 
cells in 96-well plates. We found that 7-DHC 
could be reliably measured in about 100 
Dhcr7-deficient cells while ~2,000 control 
Neuro2a cells were required to reach 
acceptable signal to noise levels.
47
 To 
establish the screening method, we used 
control Neuro2a and a set of compounds that 
included antipyschotics and antidepressants 
that are suspected of increasing levels of 7-
DHC in humans.
25,26,58,59
 We also included in 
these studies AY9944, the small molecule that is the basis of the SLOS pharmacological rodent model.
31-40
 
AY9944, aripiprazole, trazodone and haloperidol caused elevated levels of 7-DHC in control Neuro2a, 
results that are consistent with clinical findings. At 100 nM, aripiprazole, the top selling drug in 2013,
60
 
caused an increase in 7-DHC levels in control Neuro2a by over 40-fold, from 0.08 to 3.2 ng/µg protein, 
 
Figure 4. PTAD screening of Neuro2a Cells (control cells) 
in 96-well plates. Examples of the effect on 7-DHC of some 
common pharmaceuticals at 1, 10 and 100 nM in cultured 
control Neuro2a cells.  AY9944 is used in a rat SLOS 
pharmacological model, aripiprazole, haloperidol and 
trazodone are widely used atypical antipsychotics and anti-
depressants. n>3; **p<0.001, ***p<0.0001. 
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9
Figure 4.  An effect was also observed of these common pharmaceuticals on levels of desmosterol and 
lanosterol in these experiments.  Compounds that increase 7DHC tended to lower levels of desmosterol and 
lanosterol (data not shown).  The 7-DHC z’value
61
 determined for 100 nM aripiprazole vs DMSO treatment 
in control Neuro2a cells ranged from 0.2 to 0.7, an acceptable level for a screen, but one suggesting that 
follow-up validation of “hits” should be carried out. 
Drugs that lower 7-DHC levels were also detected in this assay but screening libraries of small molecules 
with Dhcr7-deficient Neuro2a cells proved more useful for finding compounds that reduce levels of the 7-
DHC and as a consequence, its toxic oxysterol derivatives.  These experiments have the advantage that 7-
DHC levels in the deficient cells (33 ng/µg protein)
47
 are about 150 times higher than in control Neuro2a 
cells and compounds that produce lower levels of 7-DHC are readily identified in incubations of the deficient 
cells. 
           
Figure 5. HTS screening. 7-DHC (pg/cell) in a 384-well plate of Dhcr7-deficient Neuro2a cells plated 
(10,000 cells/well) on 281 of the 727 compounds in the NIH Clinical Collection.  1 µM of a compound 
was pre-deposited in each well and cells were incubated for 24 h at 37
o
C. 7-DHC levels expressed as 
pg/number of cells. The left four entries are for DMSO controls (n=19) aripiprazole, bazedoxifene, and 
clomiphene at 200 nM, also shown color-coded with n>3; ***p<0.0001. 
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10
Screening the NIH Clinical Collection and Dhcr7-Deficient Cells. About 13,000 Dhcr7-deficient Neuro2a 
cells were added to each well of a 384 plate with the “test compound” concentration in the well set at 1 µM.  
In addition to test compounds, each plate had 30 control wells (DMSO only) and additional wells with three 
drugs (aripiprazole, bazedoxifene and clomiphene) that were shown to have an effect on 7-DHC in 
preliminary incubations. These compounds were included in the 384-well screen to test the reproducibility of 
the assay (5 wells each at 20 and 200 nM). The plates were then incubated for 24 hr (37°C) at which time a 
nuclear stain (Hoechst) was added and the cells were imaged by automated microscope imager. 
Subsequent to the removal of media, cells were lysed in methanol that contained isotopically labeled 
standards and the cell lysate was transferred robotically to another plate that had the PTAD reagent pre-
deposited.  The plate was immediately sealed, then agitated for 20 min  at room temperature, at which time it 
was ready for MS analysis.  The MS UPLC injector acquired samples automatically from the 384-well plate 
and the chromatography solvent was straight methanol (with no solvent programming) that allowed analysis 
of 50-60 samples/hr. We report here only data for 7-DHC.  Follow-up screens carried out in a 96-well format 
included acquisition of data for 7-DHC, lanosterol and desmosterol as a function of small molecule 
treatment. 
The output of the screen for a given test compound was the PTAD value in picogram measured in a well 
divided by cells counted per well.  Figure 5 shows output for 7-DHC in a screening of some 40% of the 
compounds in the NIH Clinical Collection on one 384-well plate. Note that of the 727 compounds tested, 
most of them have no significant effect on 7-DHC levels in Dhcr7-def cells (Figure 5), but 33 compounds on 
the plate gave increases in 7-DHC outside of 3σ of the DMSO controls. Another 40 compounds assayed on 
the plate decreased 7-DHC levels in the cells by the same 3σ criterion.  
The effect of the test compound aripiprazole on 7-DHC levels in Dhcr7-def Neuro2a was readily detected, 
200 nM of the compound doubled the level of 7-DHC in the cells. As shown in Figure 5, bazedoxifene and 
clomiphene reduced 7-DHC with statistical significance at 200 nM and clomiphene’s effect was observed at 
20 nM (data not shown). 
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11
Validation of HTS hit compounds.  We carried out follow-up assays on the compounds from the NIH 
Collection that decreased 7-DHC levels in Dhcr7-deficient cells in these cells and in human skin fibroblasts 
from SLOS affected individuals.  We also examined compounds that are structurally or therapeutically 
related to the “actives” in the NIH Collection.  These follow-up experiments were carried out in triplicate and 
included quantitative analysis of 7-DHC, desmosterol, lanosterol and cholesterol, which was included in the 
assay described in Figure 3 by extending the UPLC run to 1.2 minutes with a flow rate of 550 µL/ min and 
including d7-cholesterol in the workup. Under the conditions of this assay, cholesterol elutes at 0.93 minutes. 
GC-MS was also used in these follow-up experiments to include zymosterol (Zym), zymostenol (Zym-e), 
lathosterol (Lath), 7-dehydrodesmosterol (DHD), 4,4-dimethylzymostenol, 24-dihydrolanosterol (diHLan), 
7-DHC, desmosterol (Des) and cholesterol (Chol) in the analysis. 
Figure 6 shows the post-lanosterol sterol profiles determined by a combination of LC-MS and GC-MS 
methods for three compounds that reduce levels of 7-DHC in Dhcr7-deficient Neuro2a cells.   The 
compounds shown are representative of sub-sets of compounds, see below, that lead to similar sterol profiles 
based upon their effect on specific steps in the cholesterol biosynthesis pathway. Structures and names of 
compounds that showed a reproducible effect on the level of one of the cholesterol precursor sterols in 
Dhcr7-deficient Neuro2a cells or in human fibroblasts are presented in Table 1.    Of the compounds in Table 
1 that decrease levels of 7-DHC, there are sub-sets of compounds that have similar structures or are 
prescribed for similar purposes (Table 2).  Compounds affecting 7-DHC are statins (Row 1, A-E), selective 
estrogen receptor modulators (Row 1E and 2A-F), antipyschotics (Row 3 A-F), antimycotic/-
antibacterial/antimalarial drugs (Row 4A-F) and steroids (Row 6C-F). Thus, the statins, estrogen receptor 
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Figure 6.  Sterol profiles for Dhcr7-deficient Neuro2a cells treated with 1 µM representative 
compounds.  Mole fraction of the major post-lanosterol sterols detected by LC-MS and GC-MS.  A:  
DMSO control, B:  progesterone inhibits DHCR24 and leads to increases in desmosterol (Des) and 
dehydrodesmosterol (DHD), C:  fluphenazine inhibits EBP (∆8-7 isomerase), and leads to increases in 
zymosterol (Zym) and zymostenol (Zym-e), D:  econazole inhibits CYP51A1 demethylase and leads to 
increases in lanosterol (Lan) and dihydrolanosterol (diHLan).  Statins (data not shown) inhibit HMGCoA 
reductase, resulting in a decrease of all sterol intermediates. 
 
A. Control B. Progesterone 
C. Fluphenazine D. Econazole 
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modulators (SERMs), and antifungals were found to decrease levels of 7-DHC, providing a structure-activity 
validation of the general screening approach.  Statins affect cholesterol biosynthesis at HMG CoA-reductase, 
a stage in biosynthesis before isoprenoid formation occurs, with the consequence that all sterol levels are 
reduced, from lanosterol to cholesterol. Because of their well characterized function we independently 
verified in our system only two compounds from this group: lovastatin and pitavastatin. There have been 
reports in the literature that artemisin derivatives like those shown in Row 6, A and B, also affect cholesterol 
biosynthesis at the HMG CoA-reductase step, in this case by down-regulation of the corresponding 
gene.
62
SERMs decrease 7-DHC and alter levels of other cholesterol intermediates. The initial HTS screen 
identified four SERMs that decrease 7-DHC in Dhcr7-deficient cells, consistent with literature reports.
29,30,63-
65
 In addition to the four (clomiphene, toremifene, tamoxifen, raloxifene), we obtained several other 
commercially available SERMs (bazedoxifene, levormeloxifene, and lasofoxifene) along with the selective 
estrogen receptor downregulator fulvestrant and compared their effects on cholesterol biosynthesis in control 
and Dhcr7-deficient Neuro2a cells in an independent set of experiments that utilized both the PTAD method 
and GC-MS analysis. All of the SERMs studied were effective at decreasing 7-DHC in both control and 
Dhcr7-deficient Neuro2a cells. Assays for other post-lanosterol sterols in these experiments showed that 
biosynthetic steps other than Dhcr7 were affected by the compounds, consequently reducing 7-DHC levels in 
the cells. Tamoxifen, clomiphene and toremifene appear to have their major effect on the ∆8−7 isomerase 
with increased levels of zymostenol and zymosterol being observed while 7-DHC and cholesterol levels are 
reduced.  Raloxifene and lasofoxifene effect both the ∆8−7 isomerase and the C-24 reductase with increased 
levels of zymosterol and desmosterol found in the 1µM treatment.  Levormeloxifene appears to be one of the 
more potent compounds, exerting its affect solely on Dhcr24 with the consequent increase of desmosterol 
and 7-dehydrodesmosterol in the cells. 
Clomiphene is marketed as a mixture of geometric stereoisomers and we observed that both isomers were 
active, the separated Z and E compounds showing somewhat greater efficacy than the mixture of the two.  
We note that toremifene and tamoxifen are also obtained as stereoisomeric mixtures and our studies were 
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carried out on the isomeric mixtures.  It seems likely that the effect of concentration on various steps on 
cholesterol biosynthesis will be variable for the different compounds studied, including steroisomeric 
mixtures and, as a result, the distribution of sterols will depend both on the particular SERM studied and its 
concentration. 
Psychiatric medications alter cholesterol biosynthesis.
25
 Several compounds found to significantly 
decrease 7-DHC in the screen (3A-F) are also prescribed as antipsychotics and antidepressants.  Thus, 3A-D 
in Table 1 reduce 7-DHC levels and all are typical antidepressants having common structural features.  
Complete sterol analysis of these compounds found them to act in a way that parallels the action of the 
SERMs,
63
 increasing levels of zymosterol and zymostenol. Selected sterol analysis data is presented for these 
compounds in Supporting Information. Another set of antipsychotics/antidepressants including aripiprazole, 
trazodone and haloperidol were among the compounds that increase 7-DHC levels in the 384-well assay 
shown in Figure 5. It is noteworthy that all of these compounds are used in the treatment of depression, 
bipolar disorder, and schizophrenia. Indeed, of the compounds in our primary screen of the NIH Clinical 
Collection in Dhcr7-deficient Neuro2a cells that were shown to affect cholesterol biosynthesis in one way or 
another, over 20% are medications prescribed for bipolar disorder, depression and the like. 
Compounds with antimycotic/antibacterial/antimalarial properties decrease 7-DHC. Compounds in this 
category have well-described pharmacological properties. Several of them act as 14-α demethylase inhibitor 
(Figure 9), a step in post-squalene cholesterol biosynthesis. Chloroxine and hexachlorophene decrease 7DHC 
and desmosterol, and increase lanosterol and cholesterol. Chloroxine has bacteriostatic, fungistatic and 
antiprotozoan properties. Hexachlorophene has been used in soaps and toothpaste and also as a fungicide, 
plant bactericide and acaricide. Both compounds at 500 nM greatly decrease cell proliferation of Dhcr7-
deficient Neuro2a cells  (Supporting Information). 
Steroids and other active compounds. While progesterone’s action on DHCR24 is well documented,
66
  
several compounds identified in this screen have, to our knowledge,  not been previously associated with an 
effect on cholesterol biosynthesis. These include trimebutine, homoharringtonine, and imatinib. Trimebutine, 
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an antimuscarinic and mu opioid agonist with spasmolytic effects, decreased 7-DHC and increased 
desmosterol and lanosterol with no change in cholesterol in our cell culture at 100 nM. Imatinib, and 
homoharringtonine are protein tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia. 
Homoharringtonine is relatively toxic in our cultures, stopping proliferation of Dhcr7-deficient cells at 10 
nM and at higher concentration leading to cell death  (Supporting Information). 
Validation of HTS hits in SLOS human fibroblasts. While Dhcr7-deficient Neuro2a are convenient for use 
in the HTS screening process, we examined the “hit” compounds in human SLOS fibroblasts to validate the 
biological response in a different and more relevant cell type. Considering the biological diversity and 
 
Figure 7. SERMs alter cholesterol metabolism in SLOS human fibroblasts. SLOS HF were grown in 
96-well plates in delipidated serum in presence of different SERMs for five days. The cell viability was 
assessed by Cell Titer and the sterol measurements were normalized to the absorbance readings. All 
SERMs (100 nM) decrease 7DHC (A) with variable effects on desmosterol (B), and cholesterol (C). 
Different SERMs have variable effects on fibroblasts viability with Fulvestrant being the most toxic (D). 
At 5 µM, Clomiphene is the only SERM without an effect on viability. TAM=tamoxifen, 
CLO=clomiphene, TOR=toremifene, RAL=raloxifene, BAS=basedoxifene, LEV=levormeloxifene, 
FUL=fulvestrant. 
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complexities associated with the use of human derived cells we examined the effect of “active” small 
molecules in several different SLOS fibroblasts. 
In fibroblasts from SLOS patients we found that 10 nM of clomiphene, tamoxifen, raloxifene, fulvestrant, 
levormeloxifene and bazedoxifene resulted in a statistically significant reduction of 7-DHC without a 
measurable decrease in cholesterol levels in the cells.  Toremifene was somewhat less effective, with 100 nM 
of this compound required to cause a significant reduction of 7-DHC in SLOS HF. The results from this 
study are presented in Figure 7.    Complete data sets for the analysis of SLOS HF and control and Dhcr7-
deficient cells treated with SERMs is also presented in Supporting Information. Figure 8 shows compounds  
that consistently decreased 7-DHC in all SLOS fibroblasts. Since different SLOS HF have different 7-DHC 
levels the numbers shown are expressed as a percentage of 7-DHC present in the cells grown in the absence 
of compounds. The verified hits in SLOS HF suggest that exploring the utility of these compounds may be 
worthwhile in efforts to normalize lipid metabolism in these cells.  
 
Figure 8. Selection of small molecules that decrease 7-DHC in SLOS human fibroblasts. SLOS 
HF were grown in 96-well plates in delipidated serum in presence of different compounds for five 
days in three different SLOS fibroblasts. All of these compounds (100 nM) decrease 7DHC (A) with 
only small effects on cholesterol (B). Pitavast=pitavastatin, Perphen=perphazine, 
Trifluop=Trifluoperphanazine, Hydrox=hydroxyzine, Trimeb=trimebutine, Budes=budesonide. 
 
A. B. 
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Screening Control Neuro2a Cells. As noted, one limitation of the use of Dhcr7-deficient Neuro2a cells is 
that they are less sensitive to small molecules that increase 7-DHC than are control Neuro2a cells (since they 
already have 7-DHC levels 330 times more than control cells). Thus, while 200 nM aripiprazole results in 
doubling 7-DHC levels in Dhcr7-deficient Neuro2a, at the same concentration the compound increases 7-
DHC in control Neuro2a by a factor of over 40.  Control Neuro2a were also found to be more sensitive than 
the Dhcr7-deficient cells to trazadone, haloperidol and AY9944 although these compounds were identified as 
“actives” in the deficient cell screen. A screen of the entire NIH Collection in control Neuro2a cells is 
ongoing and the results of that effort will be reported in due course. 
Discussion 
Our screens of Dhcr7-deficient Neuro2a cells show that dozens of compounds of clinical importance can 
affect one of the steps in post-lanosterol cholesterol biosynthesis (Figure 9) and calls attention to the fact that 
pharmacological intervention can be used to reproduce, or in theory to counteract disorders involving 
disruption of sterol biosynthesis.  These disorders are rare but the consequences of mutations in the enzymes 
in the cholesterol biosynthesis pathway can be profound.
11,67
 
Our assay of control Neuro2a cells with several compounds known to affect the conversion of 7-DHC to 
 
Figure 9. Selected Transformations of Post-lanosterol Cholesterol Biosynthesis 
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cholesterol (DHCR7 in Figure 1) proved to be exquisitely sensitive and readily detects an increase in levels 
of 7-DHC in the cells at concentrations as low as 10 nM for aripiprazole, trazodone, haloperidol and 
AY9944.  For reference, patient plasma concentrations of aripiprazole, trazodone and haloperidol can be well 
above these levels.
68-70
 The effect of AY9944 on the cells was observed even at 1 nM, see Figure 4. 
Aripiprazole, trazodone, haloperidol and AY9944 were all presumed “active” small molecules that affect 
sterol homeostasis at the DHCR7 step
25,26
 and indeed, the assay identifies these compounds in the screen.
37,71
 
AY9944 has been used as the basis for one SLOS rodent model.
38
 In this protocol, pregnant rats were 
exposed to carefully programmed levels of AY9944 during gestation and the exposure was continued in the 
pups for a period of up to 3 months.  While the administration of high levels of AY9944 during pregnancy 
resulted in severe fetal malformation and miscarriage, carefully controlled maternal exposure of rats gave 
offspring that displayed many of the biochemical hallmarks and some of the phenotypic features of 
SLOS.
32,34,38
 Ratios of 7-DHC to cholesterol as high as 2:1 were found in the plasma and tissues of these 
SLOS pharmacological rat models. AY9944 failed as a cholesterol-lowering drug because it was found to be 
a teratogen, presumably due to its effect on cholesterol biosynthesis at the 7-DHC to cholesterol 
transformation.  We note that other small molecules act in a way parallel to AY9944 and these compounds 
should be considered suspect teratogens based upon common metabolism.
72
 
The Dhcr7-deficient Neuro2a cells demonstrate their primary utility as a first screen to identify compounds 
that decrease the formation of cellular 7-DHC. Table 2 shows the pharmaceutical action and prescription 
indication for those compounds identified in the NIH Clinical Collection that are approved for human use 
and that cause a decrease in 7-DHC in our screen of Dhcr7-deficient cells. We also included a few additional 
compounds in the study that are not in the NIH collection if there were reports of known activity or if they 
were structurally related to active compounds. Our screen confirms the notion that SERMs affect cholesterol 
biosynthesis by inhibiting the ∆8-7 isomerase and/or the DHCR24 since the sterol intermediates that 
accumulate upon treatment are those in the biosynthesis that are formed before the  
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Table 2. Action, Indication and FDA pregnancy designation for drugs that decrease 7-DHC in Dhcr7-
deficient Neuro2a. 
Name Action Indication FDA 
Category 
Simvastatin Statin, HMGCR inhibitor Hyperlipidemia X 
Lovastatin Statin, HMGCR inhibitor Hyperlipidemia X 
Mevastatin Statin, HMGCR inhibitor Hyperlipidemia X 
Pravastatin Statin, HMGCR inhibitor Hyperlipidemia X 
Pitavastatin Statin, HMGCR inhibitor Hyperlipidemia X 
Tamoxifen Selective estrogen receptor modulator Hormone-receptor-cancer treatment D 
Clomiphene Selective estrogen receptor modulator Ovulation induction X 
Toremifene Selective estrogen receptor modulator Hormone-receptor-cancer treatment D 
Raloxifene Selective estrogen receptor modulator Breast cancer and osteoporosis X 
Bazedoxifene Selective estrogen receptor modulator Postmenopausal osteoporosis X 
Lasofoxifene Selective estrogen receptor modulator Breast cancer and osteoporosis N 
Perphenazine Typical antipsychotic, D1/D2 antagonist Positive symptoms of schizophrenia N 
Fluphenazine Typical antipsychotic, D1/D2 antagonist Positive symptoms of schizophrenia N 
Trifluoperazine Typical antipsychotic, D1/D2 antagonist Positive symptoms of schizophrenia N 
Prochlorperazine Typical antipsychotic, D2 antagonist Antiemetic, antipsychotic, 
antivertiginoic 
N 
Doxepin Tricyclic antidepressant, SNRI class Depression, anxiety disorders N 
Molindone Atypical antipsychotic, D2, 5HT1A-2A, 
M1 
Psychoses and conduct disorder N 
Hydroxyzine Antihistaminic, anxiolytic Sedative, allergy, treat hives, runny 
nose 
C 
Econazole Antimycotic, 14-α demethylase inhibitor Dermatomycoses C 
Isoconazole Antimycotic, 14-α demethylase inhibitor Treatment of foot and vaginal 
infections 
N 
Bifonazole Antimycotic, 14-α demethylase inhibitor Topical fungal infections 
75
 
Clotrimazole Antimycotic, 14-α demethylase inhibitor Topical fungal infections C 
Chloroxine Antibacterial, not well understood Dandruff and seborrheic dermatitis C 
Hexachlorophene Organochlorine Disinfectant, topical antibacterial C 
Artemether Antimalarial, ferriprotoporphyrin IX Malaria treatment C 
Artemisinin Antimalarial, ferriprotoporphyrin IX Malaria treatment C 
Doxycycline Tetracycline Broad-spectrum antibiotic D 
Trimebutine Spasmolytic Antimuscarinic and  mu-
opioid agonist 
Irritable bowel syndrome C
76
 
Homoharringtonine Cephalotaxine,  protein synthesis 
inhibitor tyrosine kinase inhibitor 
Hematological malignancies D 
Imatinib Tyrosine-kinase inhibitor Hematological malignancies 
Treatment of multiple cancers 
D 
Budesonide Glucocorticoid Asthma, skin disorders, rhinitis, colitis C 
Magestin Progestational hormone Reproductive cancer, anorexia X 
Progesterone Progestational steroid Hormone replacement B 
Acitretin Retinoid, RXR and RAR Treatment of psoriasis X 
U18666A  Experimental N 
Categories: A, No risk in controlled human studies: Adequate and well-controlled human studies have failed to demonstrate a risk to the fetus in the 
first trimester of pregnancy (and there is no evidence of risk in later trimesters). B, No risk in other studies: Animal reproduction studies have failed to 
demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse 
effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester. C, Risk not ruled 
out: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but 
potential benefits may warrant use of the drug in pregnant women despite potential risks. D, Positive evidence of risk: There is positive evidence of 
human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may 
warrant use of the drug in pregnant women despite potential risks. X, Contraindicated in Pregnancy: Studies in animals or humans have 
demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or 
marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits. N, FDA has not yet classified 
the drug into a specified pregnancy category. 
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affected enzyme or enzymes (see Figure 9).
63,64,73-77
 The selectivity and specificity of action is dependent on 
the SERM structure and the cell type treated.  Thus, as illustrated in Figure 7, treatment of SLOS skin 
fibroblasts with each of the SERMs resulted in a decrease of 7-DHC, but the levels of sterols such as 
desmosterol, 7-dehydrodesmosterol, zymosterol and zymostenol are affected to different extents by the 
different compounds.  This can be understood by a more detailed consideration of the post-lanosterol 
cholesterol biosynthesis scheme, see Figure 9.  Levormefoxifene, bazedoxifene and raloxifene increase levels 
of desmosterol and/or 7-dehydrodesmosterol in SLOS fibroblasts, indicating that DHCR24 is inhibited by 
these compounds.  Clomiphene, tamoxifen and toremifene increase levels of zymostenol and/or zymosterol 
confirming that the ∆8-7 isomerase is inhibited. The main mechanism of action of SERMs is as estrogen 
receptor agonists in some tissues (bone, liver, and cardiovascular system), antagonists in other tissues (breast 
and brain), and mixed agonists/antagonists in the uterus. SERMs are primarily used for the prevention and 
treatment of breast cancer, osteoporosis and menopausal symptoms. In addition to their endocrine actions on 
peripheral tissues and estrogen-dependent tumors, SERMs also affect the nervous system. They have been 
used in animal studies of different experimental models of neuronal dysfunction including traumatic CNS 
and PNS injury, multiple sclerosis, and stroke. Based on the limited information available from human 
studies some of SERMs may have a positive effect on mood and cognition.
65
 It has also been shown that 
SERMs affect several signaling proteins including MAPK, PI3K, Akt, CREB, NFkB and protein kinase C 
with the positive net effect in the animal studies of neuronal dysfunction. Through their effects on signaling 
proteins, SERMs have been shown to have beneficial effects on synaptic transmission, oxidative stress, 
apoptosis and inflammation in the nervous system. They also bind to the hetero-oligomer of DHCR7 and 
DHCR24 (identified as the microsomal anti-estrogen binding site).
63
 It is of some interest that side effects 
associated with some SERM therapies have resulted in withdrawal of a drug from the clinic.  
Levormeloxifene, for example, was discontinued during a phase III trial due to a significant incidence of 
gynecologic adverse events, although the cause of those events was not ascertained.
78
 
The set of phenothiazines shown in Table 1 in Row 3(A-D) and hydroxyzine (3E) (antipsychotics) have 
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activities on sterol biosynthesis that parallel those of the SERMs.  At sub-microM levels, each of these 
compounds reduce levels of 7-DHC in Dhcr7-deficient Neuro2a cells as well as in fibroblasts from SLOS 
patients. The apparent pharmacological activity of these closely related compounds lies primarily at the ∆8-7 
isomerase, and to a lesser extent the 24 reductase (Figure 9) since elevated levels of zymostenol and 
zymosterol are detected in incubations that include these compounds. The effect of antipsychotics on 
cholesterol and fatty acid metabolism is well documented.
25
 It has been suggested that some of antipsychotics 
have class II cationic amphiphilic properties similar to amphiphile U18666A and their cytotoxic effects are 
mediated by acting on cholesterol homeostasis.
79
   It is also of interest that prochloperazine, fluphenazine and 
trifluoperazine, all of which affect the ∆8-7 isomerase, have been shown to be inhibitors of hepatitis C viral  
(HCV) entry by increasing target cell membrane fluidity.
80,81
 In a similar way, the SERMs toremifene and 
clomiphene inhibit ebola viral cell entry by a mechanism that affects the triggering of virion membrane 
fusion.
82
 It seems reasonable to suggest that the perturbation of sterol homeostasis and the consequential effect 
on membrane properties may underlie the mechanism of action for the phenothiazines with HCV and the 
SERMs with ebola. 
Summary:  We conclude that an HTS screen of small molecules that affect sterol biosynthesis in control 
and Dhcr7-deficient Neuro2a cell cultures is feasible and our method provides a basis for the further 
exploration of compounds that alter sterol homeostasis.  While the PTAD-LC-MS approach is selective and 
sensitive, the method does have limitations. Screens of large libraries at a range of concentrations is not 
possible with the current protocol since each assay requires about 1.5 minutes of instrument time. On the 
other hand, standard HTS instruments can be used in the assay, the workup of samples is straightforward, and 
multiple important sterol intermediates are determined in a single run. Because of these advantages, use of 
the PTAD-LC-MS approach proves useful when coupled with Dhcr7-deficient cells to identify compounds in 
small libraries that affect sterol biosynthesis at steps other than Dhcr7 while screens of control Neuro2a 
reveal compounds that affect the conversion of 7-DHC to cholesterol.  The approach may link small 
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molecules that exert cellular toxicities with a specific disruption of cholesterol biosynthesis and it may lead 
to the identification of molecules that normalize cholesterol biosynthesis in disorders that disrupt normal 
cholesterol homeostasis.   
Figure 10 provides a list of compounds that decrease 7-DHC at 1 µM in Dhcr7-deficient Neuro2a cells as 
well as the sterol transformation affected by the compound.  A screen of the NIH Collection at higher 
compound concentrations as well as a screen of larger libraries of pharmaceuticals and environmental agents 
that pose a threat to exposed populations seems likely to find other small molecules that affect sterol 
homeostasis.   
 
 
Experimental 
       
Figure 10. Summary of Compounds and Sterol Transformations Affected 
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Materials. Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich Co (St. Louis, MO). 
HPLC grade solvents were purchased from Thermo Fisher Scientific Inc. (Waltham, MA). All cell culture 
reagents were from Mediatech (Manassas, VA), Life Technologies (Grand Island, NY), and Greiner Bio-One 
GmBH (Monroe, NC). Standard d7-Chol was purchased from Medical Isotopes, Inc. and d7-7-DHC was 
synthesized as previously described.
41
 
13
C3-Lan and 
13
C3-Des were synthesized as described in the 
Supporting Information. 
Compound Purity. New compounds are characterized by HPLC-MS, 
13
C and 
1
H NMR spectroscopy and are 
>98% purity by these methods of analysis.  The NIH Clinical Collection of biologically active compounds is 
supplied by the NIH through the Molecular Libraries Roadmap Initiative, it is curated by the Vanderbilt 
High Throughput Screening Facility and distributed in DMSO with >95% purity. The compound molecular 
ion is identified by MS and the samples are analyzed by HPLC with evaporative light scattering or UV 
detection.  This collection is used widely in the screening community as a standard library. 
Cell Cultures: Neuro2a and human fibroblasts. The neuroblastoma cell line Neuro2a was purchased from 
American Type Culture Collection (Rockville, MD). Dhcr7-deficient Neuro2a cells were generated as 
previously described.
42
 All cells were subcultured once a week, and the culture medium was changed every 
two days. Control (GM05399, GM05565, GM05758) and SLOS (GM05788, GM03044) human fibroblasts 
were purchased from the Coriell Institute, UMB#727 was obtained from NICHD Brain and Tissue Bank and 
8019 and 35878 originated from SLOS patients.  All cell lines were maintained in DMEM supplemented 
with L-glutamine, 10% fetal bovine serum (FBS; Thermo Scientific HyClone, Logan, UT), and 
penicillin/streptomycin at 37ºC and 5% CO2. All cultured SLOS and control human fibroblasts used were 
passage 8-20. Delipidated FBS medium did not have detectable cholesterol level. At the end of experiment, 
cells were washed with ice-cold PBS two times, scraped into 5 mL of ice-cold PBS, centrifuged at 200X g 
for 10 min at +4°C, PBS was removed and the cell pellets frozen at -80°C until analysis.  
The screening method. Chemicals were deposited to 384 cell culture plate (Greiner Bio-One) using Labcyte 
Echo 550/555 (Sunnyvale, CA) liquid handler equipped in the Vanderbilt University High Throughput 
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Screening Facility. 25 µL of control and Dhcr7-deficient Neuro2a cells in reduced FBS media (0.5%) with a 
density of 10,000 and 13,000 cells/well respectively, were dispensed to the wells using a Multidrop Combi 
(ThermoScientific) instrument. The cells were placed in an incubator for 24 h at which time 10 µL Hoechst 
dye (40 ng/µL) (Molecular Probes) was added using the Multidrop Combi.  The cells were incubated at room 
temperature for 30 min in the dark and imaged using an ImageXpress Micro XL (Molecular Devices, 
Sunnyvale, CA) with a 10X objective. After removing the media, 80 µL MeOH containing internal standards 
(6.5 ng for d7-7-DHC, 100 ng for 
13
C3-Des and 75 ng for 
13
C3-Lano/well) was added using the Multidrop 
Combi. The plate was placed on an Orbital shaker for 20 min at room temperature and centrifuged for 10 min 
using a Sorvall swing rotor. The supernatant was transferred by automated liquid handler Agilent Velocity 11 
Bravo to a PTAD-predeposited plate (Waters #186002631, 100 µL flat bottom). The plates were immediately 
sealed with Easy Pierce Heat Sealing Foil (ThermoScientific AB-1720) followed by 20 min agitation on an 
Orbital shaker at room temperature. The sealed plates were kept in -80°C until LC-MS analysis.  
LC-MS (SRM) analysis. The sealed plates were placed in an Acquity UPLC system equipped with ANSI-
compliant well plate holder. 10 µL was injected on to the column (Acquity UPLC BEH C18, 1.7 µm, 2.1 x 
50 mm) with 100% MeOH (0.1% acetic acid) mobile phase for 1 min runtime at a flow rate of 300 µL/min. 
The monitored transitions included: 7-DHC 560365, d7-7-DHC 567372, desmosterol 592365, 
13
C3-
desmosterol 595368, lanosterol 634602, 
13
C3-lanosterol 637605 with retention times of 0.8, 0.5, and 
0.6 min, respectively.  
Lipid extraction, separation, and GC-MS analyses of sterols in cells.  Verification of the hits obtained from 
the initial screening was carried out with varying concentrations of the compounds of interest.  In addition, a 
more complete sterol profile was determined.  The experiment was carried out in 96 well plates as described 
above for the 384 well plates.  After cells were counted using the ImageXpress Micro XL with 10X 
objective, the medium was removed.  The cells were washed with PBS, the buffer removed and the plates 
were stored at -80°C until taken for sterol analysis.  The protocol for analysis was as follows: to each well 
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was added 10 µL BHT/TPP solution (2.5 mg TPP and 1 mg BHT in 1 mL EtOH), 10 µL internal standard 
solution (0.87 nmol for d7-Chol, 0.033 nmol for d7-7-DHC, 0.25 nmol for 
13
C3-Des and 0.23 nmol for 
13
C3-
Lan/well), and 200 µL MeOH.  The plate was agitated on an Orbital shaker for 20 min at room temperature.  
An aliquot (100 µL) of the supernatant was transferred to a PTAD-pre-deposited plate, sealed with Easy 
Pierce Heat Sealing Foil followed by 20 min agitation on an Orbital shaker at room temperature, and 
analyzed by LC-MS as described above.  If the LC flow rate was increased to 500 µL/min with a run time of 
1.5 min, cholesterol could be included in the analysis (Chol 369, d7-Chol 376).  
For GC-MS analysis, the remaining sample in each well was transferred to a vial and concentrated on a 
SpeedVac concentrator.  To each vial was added N,O-bis(trimethylsilyl)-trifluoroacetamide (BSTFA, 50 µL), 
the sample vortexed well, and allowed to react for 30 min.  The sample (5 µL) was injected onto the column 
(SPB-5, 0.25 µm, 0.32 mm x 30 m) with a temperature program of 220-300° (5 min) at 20°/min and helium 
flow rate of 2.0 mL/min.  The data was collected in full scan mode and the following ions extracted for 
quantitation relative to d7-Chol:  458 for cholesterol, zymostenol, lathosterol; 456 for zymosterol, 
dehydrolathosterol; 349 (M-105) for dehydrodesmosterol; 393 (M-105) for lanosterol; 395 (M-105) for 
dihydrolanosterol; 486 for dimethylzymostenol; and 465 for d7-cholesterol.  Desmosterol and 7-DHC were 
not analyzed by GC-MS because they co-elute.  Any sterol not listed above was not detected by GC-MS.  All 
data was normalized to cell count.  All calculations of variability, standard deviation (SD) and normalized 
SD were performed in Microsoft Excel or GraphPad Prism. 
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